NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, herewith provides additional details on its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus (BDBV) and other Ebola viruses in the Democratic Republic of Congo ("DRC").

The trial is proceeding as designed. This clinical trial is being conducted in two parts. Enrollment in the first part, Phase IIA, began on or about September 23, 2026. Patients are being enrolled slowly, in a cautious approach, because NV-387 is a new chemical entity. As the clinical experience with NV-387 increases, enrollment may speed up. This part requires only a small number of patients.

In Phase IIA, the trial is designed to evaluate the dosage regimen that is tolerable in patients with clinical Ebola Virus Disease (EVD). The purpose of the Phase IIA part is to determine the optimal dosing regimen (amount, frequency, and schedule in number of days) that remains well tolerated in terms of safety signals (toxicity) in the context of the issues caused by the Ebola Bundibugyo viral disease itself. The clinical symptoms of the Ebola BDBV disease are complex, and possibly different from prior Ebola virus outbreaks i.

It is expected that when the optimal dosage regimen is administered, signs of reduction in viral load would be seen, and potentially, recovery in the patients would also be seen. However, the Phase IIA part is not designed for evaluating efficacy of the drug in a statistical sense. It is designed to provide a quick go-nogo gate to support starting the Phase IIB, which is a randomized clinical trial of NV-387 Oral Gummies designed for evaluating efficacy in treating Ebola patients.

After a dosage regimen is identified, it will be used in an expanded, randomized, controlled clinical trial, Part IIB, to evaluate effectiveness of the Oral treatment drug NV-387 Oral Gummies.

NV-387 is designed to attack the virus and reduce the viral load in the body.